Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
7.05
USD
|
+4.29%
|
|
-9.38%
|
+69.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
0.7866
|
106.6
|
57.01
|
36.17
|
91.71
|
195.9
|
-
|
-
|
Enterprise Value (EV)
1 |
0.7866
|
106.6
|
57.01
|
36.17
|
91.71
|
195.9
|
195.9
|
195.9
|
P/E ratio
|
-0.02
x
|
-2.15
x
|
-2.16
x
|
-0.87
x
|
-1.41
x
|
-5.72
x
|
-30.1
x
|
7.54
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
64.8
x
|
16
x
|
13.3
x
|
44.4
x
|
6.83
x
|
2.78
x
|
1.49
x
|
EV / Revenue
|
-
|
64.8
x
|
16
x
|
13.3
x
|
44.4
x
|
6.83
x
|
2.78
x
|
1.49
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37
|
5,949
|
7,356
|
10,047
|
22,046
|
27,786
|
-
|
-
|
Reference price
2 |
21.25
|
17.92
|
7.750
|
3.600
|
4.160
|
7.050
|
7.050
|
7.050
|
Announcement Date
|
5/5/20
|
3/31/21
|
3/25/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1.646
|
3.555
|
2.719
|
2.065
|
28.68
|
70.5
|
131.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-21.3
|
-24.53
|
-33.85
|
-38.18
|
-34.86
|
-12.2
|
35.79
|
Operating Margin
|
-
|
-1,294.23%
|
-690.04%
|
-1,245.05%
|
-1,849.01%
|
-121.55%
|
-17.31%
|
27.28%
|
Earnings before Tax (EBT)
1 |
-
|
-24.16
|
-25.65
|
-36.51
|
-47.68
|
-35.71
|
-12.37
|
35.67
|
Net income
1 |
-8.879
|
-24.21
|
-25.65
|
-36.51
|
-47.68
|
-35.71
|
-12.32
|
29.1
|
Net margin
|
-
|
-1,470.9%
|
-721.49%
|
-1,342.7%
|
-2,308.86%
|
-124.5%
|
-17.47%
|
22.18%
|
EPS
2 |
-1,047
|
-8.350
|
-3.590
|
-4.120
|
-2.940
|
-1.232
|
-0.2340
|
0.9350
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/5/20
|
3/31/21
|
3/25/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2.108
|
0.378
|
0.797
|
0.906
|
0.639
|
0.597
|
0.495
|
0.434
|
0.539
|
3.139
|
5.371
|
7.894
|
12.28
|
13.16
|
16.29
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.658
|
-7.543
|
-8.984
|
-7.801
|
-7.855
|
-8.325
|
-7.997
|
-10.56
|
-11.3
|
-10.28
|
-10.07
|
-8.967
|
-6.549
|
-3.5
|
-0.3
|
Operating Margin
|
-220.97%
|
-1,995.5%
|
-1,127.23%
|
-861.04%
|
-1,229.26%
|
-1,394.47%
|
-1,615.56%
|
-2,432.26%
|
-2,097.22%
|
-327.43%
|
-187.53%
|
-113.59%
|
-53.31%
|
-26.61%
|
-1.84%
|
Earnings before Tax (EBT)
1 |
-5.348
|
-8.203
|
-9.657
|
-8.505
|
-8.472
|
-9
|
-7.202
|
-20.34
|
-11.14
|
-11.11
|
-9.921
|
-8.773
|
-6.382
|
-3.5
|
-0.3
|
Net income
1 |
-5.348
|
-8.203
|
-9.657
|
-8.505
|
-8.472
|
-9
|
-7.202
|
-20.34
|
-11.14
|
-11.11
|
-9.921
|
-8.773
|
-6.382
|
-2.8
|
-0.3
|
Net margin
|
-253.7%
|
-2,170.11%
|
-1,211.67%
|
-938.74%
|
-1,325.82%
|
-1,507.54%
|
-1,454.95%
|
-4,686.64%
|
-2,066.05%
|
-353.97%
|
-184.72%
|
-111.13%
|
-51.95%
|
-21.28%
|
-1.84%
|
EPS
2 |
-0.6900
|
-1.000
|
-1.180
|
-0.9200
|
-0.8600
|
-0.7700
|
-0.5800
|
-1.140
|
-0.4800
|
-0.4500
|
-0.3475
|
-0.2850
|
-0.1650
|
-0.1350
|
-0.0950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/22
|
5/10/22
|
8/8/22
|
11/8/22
|
3/27/23
|
5/22/23
|
8/9/23
|
11/13/23
|
3/26/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0.06
|
0.06
|
0.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.2%
|
0.08%
|
0.04%
|
Announcement Date
|
5/5/20
|
3/31/21
|
3/25/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
7.05
USD Average target price
21.2
USD Spread / Average Target +200.71% Consensus |
1st Jan change
|
Capi.
|
---|
| +69.47% | 196M | | -13.72% | 20.65B | | +8.00% | 14.03B | | +11.15% | 10.41B | | -20.38% | 1.99B | | +3.10% | 1.76B | | +8.31% | 1.33B | | +6.05% | 552M | | -.--% | 421M | | +11.28% | 88.9M |
Medical Prosthetics
|